Molecular Partners AG (NASDAQ:MOLN) Short Interest Down 26.4% in September
Molecular Partners AG (NASDAQ:MOLN) Short Interest Down 26.4% in September
Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 19,800 shares, a decrease of 26.4% from the August 31st total of 26,900 shares. Based on an average trading volume of 10,400 shares, the short-interest ratio is currently 1.9 days.
分子合夥公司(納斯達克：Moln-Get Rating)是空頭股數9月份大幅下跌的目標。截至9月15日，空頭股數共有1.98萬股，比8月31日的2.69萬股減少了26.4%。以10,400股的平均成交量計算，目前短息比率為1.9天。
Molecular Partners Trading Up 7.7 %
分子合作伙伴交易上漲7.7%
MOLN traded up $0.48 during trading on Friday, hitting $6.69. 4,238 shares of the stock traded hands, compared to its average volume of 7,740. The firm has a 50-day moving average of $6.31 and a 200 day moving average of $9.43. Molecular Partners has a 12-month low of $5.50 and a 12-month high of $32.04.
在週五的交易中，Moln的交易價格上漲了0.48美元，達到6.69美元。該股有4,238股易手，而其平均成交量為7,740股。該公司的50日移動均線切入位在6.31美元，200日移動均線切入位在9.43美元。Molecal Partners的股價為5.50美元，為12個月低點，12個月高位為32.04美元。
Molecular Partners (NASDAQ:MOLN – Get Rating) last announced its quarterly earnings results on Thursday, August 25th. The company reported ($0.15) earnings per share for the quarter. The business had revenue of $12.19 million for the quarter. On average, research analysts anticipate that Molecular Partners will post 3.79 EPS for the current year.
分子合夥公司(納斯達克：Moln-Get Rating)最近一次公佈季度收益是在8月25日星期四。該公司公佈了本季度每股收益(0.15美元)。該業務本季度的收入為1219萬美元。研究分析師平均預計，分子合作伙伴公司本年度的每股收益將達到3.79歐元。
Analysts Set New Price Targets
分析師設定新的價格目標
Institutional Inflows and Outflows
機構資金流入和流出
A hedge fund recently raised its stake in Molecular Partners stock. Federated Hermes Inc. grew its stake in Molecular Partners AG (NASDAQ:MOLN – Get Rating) by 94.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 457,037 shares of the company's stock after purchasing an additional 221,743 shares during the quarter. Federated Hermes Inc. owned about 1.41% of Molecular Partners worth $9,264,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.70% of the company's stock.
一家對衝基金最近增持了分子合夥公司的股票。聯合愛馬仕公司最近提交給美國證券交易委員會的文件顯示，今年第一季度，該公司在分子合夥公司(納斯達克代碼：Moln-Get Rating)的持股增加了94.2%。該機構投資者在本季度額外購買了221,743股後，持有該公司457,037股股票。截至最近一個季度末，聯合愛馬仕公司持有分子合夥公司約1.41%的股份，價值9,264,000美元。機構投資者和對衝基金持有該公司2.70%的股票。
About Molecular Partners
關於分子夥伴
(Get Rating)
(獲取評級)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
分子夥伴公司是一家臨牀階段的生物製藥公司，專注於治療性蛋白質的發現、開發和商業化。它的候選產品包括用於治療新血管濕性老年性黃斑變性和糖尿病黃斑水腫的候選DARPin藥物Abempar，該藥物處於第三階段臨牀試驗；以及針對SARS-CoV-2病毒的多特異性DARPin候選藥物MP0420。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- Let Paychex Stock Work Hard For You
- 免費獲取StockNews.com關於分子夥伴的研究報告(Moln)
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- Keurig Dr Pepper與規模更大的競爭對手可口可樂(Coke&Pepsi)相比如何？
- 讓Paychex股票為您努力工作
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到分子合作伙伴的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收分子合作伙伴和相關公司的最新新聞和分析師評級的每日摘要。
譯文內容由第三人軟體翻譯。